Halozyme Therapeutics Good News About Approvals. See Also: Arrowhead Pharmaceuticals Good Trial Results for Liver Diseases  

Halozyme Therapeutics Approvals for DARZALEX®SC
Halozyme Therapeutics (HALO) announced that the European Commission (EC) has granted Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX® SC in the European Union. 

The first authorization relates to the use of DARZALEX® SC in combination with bortezomib . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.